Since the mutation rate of CTNNB1 gene is relatively higher in HCC than in other types of cancer (Supplementary Fig. 6), clinical trials of ICIs should be conducted or subanalyzed for HCC with wild-type and mutated β-catenin separately. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.